CME Group (CME) Financials

CME Group’s latest results show continued earnings growth, although operating cash flow and quarterly momentum weakened in Q2 2026. Revenue was $1.71 billion, up modestly from $1.69 billion in Q2 2025 and meaningfully above the $1.23 billion reported in Q2 2022. Net income attributable to common shareholders increased to $1.04 billion from $1.03 billion a year earlier, while diluted EPS rose to $2.88 from $2.81. Over the longer period, diluted EPS has increased from $1.87 in Q3 2022 to $2.88 in Q2 2026.

Profitability remains strong, but Q2 was weaker sequentially. Revenue declined 9.2% from $1.88 billion in Q1 2026, and net income fell 9.7% from $1.15 billion. Operating income decreased to $1.11 billion from $1.31 billion in Q1, while the operating margin narrowed to approximately 64.9% from 69.7%. The year-over-year operating margin also slipped from roughly 66.8% in Q2 2025.

CME continues to generate substantial cash from its core operations. Q2 operating cash flow was $947.1 million, more than enough to cover approximately $30.3 million of capital expenditures and investment purchases. However, operating cash flow declined 10.5% from Q2 2025 and 24.9% from Q1 2026. The latest quarter also included a $194.1 million use of cash from changes in operating assets and liabilities, compared with a smaller $65 million use in Q2 2025.

The balance sheet remains supported by stable debt levels and significant liquidity. Cash and equivalents totaled $2.14 billion at June 30, 2026, up from $1.98 billion a year earlier, although down from $2.39 billion at the end of Q1. Long-term debt was essentially unchanged at $3.42 billion compared with both Q2 2025 and Q2 2024. CME’s reported assets and liabilities are heavily influenced by clearing-related balances, including very large “other current assets” and “other current liabilities,” so those figures should not be interpreted like a conventional industrial company’s working capital.

• Strong long-term earnings progression: Diluted EPS increased from $1.87 in Q3 2022 to $2.88 in Q2 2026, supported by sustained profitability and modest share-count management.
• Revenue remains near record levels: Q2 2026 revenue of $1.71 billion was slightly higher than the restated Q2 2025 figure and substantially above comparable 2022 levels.
• High cash conversion: CME generated $947.1 million of operating cash flow in Q2, while capital expenditures were only $23.6 million, demonstrating the relatively low capital intensity of its exchange business.
• Shareholder returns remain substantial: CME repurchased $698.2 million of common stock and paid $468.1 million in dividends during Q2. The company also paid a large $2.70 billion dividend in Q1 2026.
• Debt is broadly stable: Long-term debt has remained close to $3.4 billion across the reported periods, providing financial stability despite large changes in clearing-related balance-sheet accounts.
• Investment income is a significant earnings factor: Interest and investment income exceeded $1.5 billion in Q2 2026, but much of this was offset by a $1.26 billion other expense. Investors should monitor how much of this volatility is tied to clearing operations and market conditions.
• Balance-sheet growth is difficult to interpret: Total assets rose to $194.7 billion from $179.9 billion a year earlier, largely because of large clearing-related current asset and liability balances rather than traditional operating assets.
• Sequential results weakened: Q2 revenue, operating income, net income and operating cash flow all declined from Q1 2026, indicating weaker near-term momentum.
• Operating margin compressed: Q2 operating expenses rose to $365.6 million from $341.1 million in Q2 2025, causing operating income to fall 2.0% year over year despite modest revenue growth.
• Cash declined during Q2: Net cash decreased by $7.17 billion in the quarter, primarily because of an $8.09 billion financing outflow categorized largely as other financing activities. Although these movements may reflect clearing-related activity, they warrant monitoring because they reduced cash and equivalents by roughly $247 million from the prior quarter.